A Study to Test GlaxoSmithKline's (GSK) Candidate Vaccine-GSK1437173A for Prevention of Shingles in Children With Kidney Transplant

Launched by GLAXOSMITHKLINE · Jul 1, 2019

Keywords

ClinConnect Summary

This clinical trial is studying a new vaccine called GSK1437173A, developed by GlaxoSmithKline, aimed at preventing shingles, also known as Herpes Zoster, in children who have received kidney transplants. Shingles can be a painful condition caused by the same virus that causes chickenpox. The trial is specifically looking at children aged 1 to 17 years who are at risk because they have weakened immune systems due to their transplant. Researchers want to understand how safe the vaccine is, how well it works in making the body immune to shingles, and how it reacts in these children.

To be eligible for this trial, children must have had a kidney transplant more than six months ago and be stable in their kidney function. They also need to have received some form of vaccination against chickenpox in the past or have had chickenpox before their transplant. Parents or legal guardians must provide consent for their child to participate, and the child may also need to agree depending on their age. Participants will receive two doses of the vaccine and will be monitored for any side effects and how well the vaccine protects them from shingles. This study is important because it could help provide better protection for children who have undergone kidney transplants, a group that is at higher risk for infections.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects' parent(s)/Legally Acceptable Representative(s) \[LAR(s) who, in the opinion of the investigator, can and will comply, with the requirements of the protocol
• • Written or witnessed/thumb printed informed consent obtained from the parent(s)/LAR(s) of the subject prior to performance of any study specific procedure.
• • Written informed assent obtained from the subjects when applicable according to local requirements.
• • A male or female between, and including, 1 and 17 years of age at the time of randomisation (Visit Day 1)
• • Body weight ≥ 6 kg/13.23 pounds.
• * A subject is eligible if they meet at least one of the following criteria:
• • Documented previous VZV vaccination OR
• • Medically verified varicella (with source documentation) OR
• • Seropositive for VZV prior to transplantation.
• • Subjects with renal transplant more than six months (180 days) prior randomization (Visit Day 1)
• • Subject who has received an ABO compatible allogeneic renal transplant (allograft).
• • Subject with stable renal function with stability defined as \<20% variability between the last two creatinine measurements or based on investigator opinion after review of multiple creatinine measurements.
• • Subject receiving maintenance immunosuppressive therapy for the prevention of allograft rejection for a minimum of one month (30 days) prior to randomization (Visit Day 1).
• • Female subjects of childbearing potential may be enrolled in the study, if the subject
• • has practiced adequate contraception for 30 days prior to Visit Day 1 and has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series
• Exclusion Criteria:
• • Medical conditions
• • Any primary kidney disease with a high incidence of recurrent primary kidney disease within the allograft
• • Evidence of recurrent primary kidney disease within the current allograft
• • Previous allograft loss secondary to recurrent primary kidney disease
• • History of more than one organ transplanted (that is, kidney-liver, simultaneous double kidney or kidney-other organ(s) transplanted).
• • Subjects with an episode of acute allograft rejection over the six months (180 days) prior to enrolment
• • Panel Reactive Antibodies (PRA) calculated PRA (cPRA) or Calculated Reaction Frequency (cRF) score that is unknown at the time of transplant
• • VZV serostatus unknown prior to transplant
• • Subjects with advanced chronic kidney disease
• • Evidence of significant proteinuria (≥ 200 g/mol creatinine) believed to be of renal origin (an example of non-renal origin is proteinuria from mucus in a reconstructed bladder)
• • Subjects without multiple dialysis options in the event acute or chronic dialysis needed.
• • History of unstable or progressive neurological disorder.
• • Subjects ≤ 5 years of age with a history of one or more simple or complex febrile seizures
• • Subjects \> 5 years with history of one or more complex febrile seizures
• • Occurrence of a varicella or HZ episode by clinical history within the 6 months (180 days) preceding Visit Day 1
• * Any autoimmune disease, with the following exceptions which do not constitute an exclusion criterion:
• • IgA nephropathy
• • Rapidly progressive glomerulonephritis
• • Membranous glomerulonephritis
• • Idiopathic Type I membranoproliferative glomerulonephritis
• • Diabetes mellitus (type 1 and 2) with diabetic nephropathy
• • Confirmed or suspected Human Immunodeficiency Virus or primary immunodeficiency disease
• • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study
• • History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine
• • Any condition which, in the judgement of the investigator would make intramuscular injection unsafe.
• • Atypical Haemolytic Uraemic Syndrome.
• • Prior/Concomitant therapy
• • Use of any investigational or non-registered product other than the study vaccine during the period starting 30 days before Visit Day 1 (Day -29 to Day -1), or planned use during the study period.
• • Subject in receipt of treatment for rejection during the six months (180 days) prior to enrolment.
• • Use of anti-CD20 or other B-cell monoclonal antibody agents within 1 year of Visit Day 1 or planned administration during the duration of the study.
• • Administration of blood products 3 months (90 days) prior to Visit Day 1 or planned administration during the duration of the study.
• • Administration of immunoglobulins 6 months (180 days) prior to Visit Day 1 or planned administration of immunoglobulins during the duration of the study.
• • Administration or planned administration of a vaccine within 30 days prior to Visit Day 1 up to Visit Month 2 with the exception of an inactivated or subunit influenza vaccine which may be given 8 days prior to or 14 days after Visit Day 1 and 8 days prior to or 14 days after Visit Month 1.
• • Previous vaccination against HZ
• • Varicella vaccination within the 6 months (180 days) preceding Visit Day 1
• • Planned administration during the study of an HZ or varicella vaccine (including an investigational or non-registered vaccine) other than the study vaccine
• • Prior/Concurrent clinical study experience
• • • Concurrent or planned participation in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product
• • available locally through compassionate use programs,
• • submitted for and pending local/country registration,
• • approved and registered for use in other countries with well-documented Summary of Product Characteristics or Prescribing Information
• • The name of the active component(s) of these immunosuppressants must be provided in the concomitant medication listing
• • Other exclusions
• • Child in care
• • Pregnant or lactating female
• • Female planning to become pregnant or planning to discontinue contraceptive precautions (if of childbearing potential) between one month (30 days) prior to Visit Day 1 through two months (60 days) after Visit Month 1.
• • Evidence or high suspicion, in the opinion of the investigator, of non-compliance or non-adherence to use of induction and/or maintenance immunosuppressive therapies.
• • Failure to fully complete the 7-day pre-vaccination diary card distributed at the Pre-vaccination visit
• • Completion must cover the 7 days immediately prior to randomisation (Visit Day 1).
• • Completion is defined as a minimum of 6 days completed.
• • Subjects with less than 6 days completed may be offered a new date for Visit Day 1 and the opportunity to comply with the completion of the 7-day pre-vaccination diary card prior to the new planned Visit Day 1.
• • Any study personnel or their immediate dependants, family, or household member.